Published in Clinical Trials Week, September 25th, 2006
According to a recent report published in the journal Gynecologic Oncology, researchers in the United States conducted a study "to evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks) resistant ovarian cancer. Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.